Kura Oncology Inc KURA.OQ KURA.O is expected to show a fall in quarterly revenue when it reports results on March 5 for the period ending December 31 2025
The San Diego California-based company is expected to report a 0.6% decrease in revenue to $53.554 million from $53.88 million a year ago, according to the mean estimate from 13 analysts, based on LSEG data.
LSEG's mean analyst estimate for Kura Oncology Inc is for a loss of 61 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Kura Oncology Inc is $28.00, about 222.6% above its last closing price of $8.68
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.89 | -0.85 | -0.85 | Met | 0.2 |
Jun. 30 2025 | -0.48 | -0.46 | -0.75 | Missed | -63.4 |
Mar. 31 2025 | -0.45 | -0.39 | -0.66 | Missed | -68.9 |
Dec. 31 2024 | -0.63 | -0.64 | -0.22 | Beat | 65.5 |
Sep. 30 2024 | -0.61 | -0.63 | -0.63 | Met | -0.7 |
Jun. 30 2024 | -0.62 | -0.63 | -0.59 | Beat | 6.2 |
Mar. 31 2024 | -0.54 | -0.55 | -0.59 | Missed | -7.3 |
Dec. 31 2023 | -0.54 | -0.55 | -0.55 | Met | -0.1 |
This summary was machine generated March 3 at 13:42 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)